IndraLab

Statements



reach
"Glyburide (12), a well-known FDA approved antidiabetic drug is another sulfonylurea compound that inhibits the NLRP3 inflammasome and secretion of IL-1β induced by LPS and ATP in BMDMs [130]."

reach
"The selected chemicals, tertiary sulfonylurea compounds, inhibited NLRP3 and AIM2 inflammasome activation ."

reach
"Glemepiride, a known anti-diabetic drug (sulfonylurea), has been shown to inhibit the ATP enzyme activity of NLRP3, but its high dose required to inhibit NLRP3 in vivo causes lethal hypoglycemia (Lamkanfi et al., 2009)."

reach
"However, unlike for CY-09, the molecular target and mechanism by which MCC950 and CRID3 and related sulfonylurea molecules inhibit the NLRP3 inflammasome remains enigmatic."

reach
"Glyburide (glibenclamide), a sulfonylurea drug used for the treatment of type-2 diabetes, is known to inhibit ATP sensitive K + channels and can thus prevent NLRP3 inflammasome activation."

reach
"Consistently, high percentage of irregular axons was observed in sciatic nerve of 400 mg/kg HD-intoxicated rats ( Fig. 2 F), indicating axon damage.To further verify whether NLRP3 inflammasome activat[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

reach
"The sulfonylurea drug glyburide, usually used clinically to treat type II diabetes, is a non selective antagonist of NALP3 and could prevent activation of the NALP3 inflammasome and crystal induced IL-1beta secretion."

reach
"Agarwal et al. (2020) reported that thiazolo-alkenyl sulfonylurea derivative 7 inhibited the activation of NLRP3 by inhibiting ASC oligomerisation (Agarwal, Pethani, et al., 2020)."

reach
"The mechanism by which sulfonylurea compounds inhibit NLRP3 activation is currently not understood."

reach
"As mentioned above, the type 2 diabetes mellitus (T2DM) drug, glyburide, is also a sulfonylurea that inhibits NLRP3 [ 12 ] and several other sulfonylureas, such as sulofenur and glimepiride, can also [MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

reach
"Interestingly, Glyburide, a frequently used sulfonylurea drug for the treatment of type 2 diabetes, has been shown to inhibit the NLRP3 inflammasome ( Lamkanfi et al., 2009; Masters et al., 2010 ), an[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

reach
"In 2017, Hill et al. (2017) synthesized a series of MCC950, sulfonylurea derivatives that can inhibit NLRP3 inflammasome with nanomolar potencies and also inhibit insulin secretion."

reach
"Furthermore, inhibition of NLRP3 inflammasome by glybenclamide, a sulfonylurea inhibitor of NLRP3 inflammasome, was found to be able to suppress microglial proinflammatory activation and nuclear factor-kappaB activation induced by paraquat and maneb."

reach
"Glyburide, a sulfonylurea, is reported to inhibit the activation of NLRP3 inflammation by blocking the ATP-sensitive K+ channels (KATP)[61]."

reach
"Glyburide (International Nonproprietary Name : glibenclamide), an antidiabetic sulfonylurea drug, inhibits NLRP3 inflammasome activation by several stimuli, without affecting the NLRC4 or NLRP1 inflammasomes [XREF_BIBR]."

reach
"Likewise, a sulfonylurea drug Glyburide which is widely used for the treatment of Diabetes type 2, was also shown to inhibit the NLRP3 inflammasome."

reach
"The results confirm that the NLRP3 inflammasome and local IL-1beta (+) F4/80 (+) Ly6C (+) macrophages as novel players in the pathogenesis of VCP associated myopathy and identified the sulfonylurea MCC950 inhibitor of the NLRP3 inflammasome with promising therapeutic potential for the treatment of VCP associated myopathy."

reach
"Moreover, the present study identified the sulfonylurea MCC950 inhibitor of the NLRP3 inflammasome as a promising therapeutic drug for the treatment of VCP associated myopathy."

reach
"Together, these results suggest that : (i) the NLRP3 inflammasome and local IL-1beta (+) F4/80 (+) Ly6C (+) macrophages as novel players in the pathogenesis of VCP associated myopathy; and (ii) identified the sulfonylurea MCC950 inhibitor of the NLRP3 inflammasome with promising therapeutic potential for the future treatment of patients with VCP associated myopathy."

reach
"The sulfonylurea Glyburide inhibits ATP sensitive K + (K ATP) channels and has been shown to inhibit NLRP3 inflammasome activation, without affecting the NLRP1 or NLRC4 inflammasomes."

reach
"Glibenclamide (GBC), a sulfonylurea drug used for diabetes, has been shown to inhibit the NLRP3 inflammasome pathway, suppress microglia and astrocyte activation, and support favorable neurologic outcomes following rodent CA (93)."

reach
"Glyburide, the most widely used sulfonylurea drug for type 2 diabetes in the US, inhibits the Nalp3 inflammasome."

reach
"As evidence showed that another sulfonylurea drug glipizide also inhibited Sur1 containing K ATP channels but failed to inhibit NLRP3 inflammasome activation."

reach
"While Lamkanfi et al clearly showed this drug directly inhibits NLRP3, it is also a widely used sulfonylurea drug for the treatment of type 2 diabetes where it acts at ATP-sensitive K (KATP) channels and Kir6.2."

reach
"Compounds with a sulfonylurea fragment can specifically inhibit the activation of the NLRP3 inflammasome in the activation phase without affecting the priming stage dependent on NF-κB signaling [83]."
| PMC

reach
"Finally, we treated monocytes and MDC with 100 muM glibenclamide, a sulfonylurea drug which inhibits NLRP3 activation but not NLRC4 activation [XREF_BIBR]."

reach
"Glibenclamide is a sulfonylurea inhibitor of NLRP3 inflammasome through the K + channel P2 × 7 ( Lamkanfi et al., 2009 ; Yang et al., 2019a )."